Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study

Annals of the Rheumatic Diseases

Volumn 72, Issue 7, 2013, Pages 1217-1220

  Elhai, Muriel ^a   Meunier, Marine ^a   Matucci Cerinic, Marco ^b   Maurer, Britta ^c   Riemekasten, Gabriela ^d   Leturcq, Tifenn ^a   Pellerito, Raffaele ^e   Von Muḧlen, Carlos Alberto ^f   Vacca, Alessandra ^g   Airo, Paolo ^h   Bartoli, Francesca ^b   Fiori, Ginevra ^b   Bokarewa, Maria ⁱ   Riccieri, Valeria ^j   Becker, Mike ^d   Avouac, Jérôme ^a   Müller Ladner, Ulf ^k   Distler, Oliver ^c   Allanore, Yannick ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Department of Biomedicine   (Italy)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e MAURIZIANO HOSPITAL   (Italy)

^f Rheuma Clinic for Rheumatic Diseases   (Brazil)

^g University Clinic AOU of Cagliari   (Italy)

^h UNIVERSITY OF BRESCIA   (Italy)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; METHOTREXATE; STEROID; TOCILIZUMAB;

ADULT; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DAS28; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; LOW DRUG DOSE; LUNG FIBROSIS; MALE; MULTICENTER STUDY (TOPIC); MYOPATHY; NAUSEA; OBSERVATIONAL STUDY; POLYARTHRITIS; PRIORITY JOURNAL; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ARTHRITIS; SYSTEMIC SCLEROSIS; TREATMENT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; MUSCULAR DISEASES; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84878404903     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202657     Document Type: Article

References (21)

1. Avouac J, Walker U, Tyndall A, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37:1488-501.
2. Avouac J, Clements PJ, Khanna D, et al. Articular involvement in systemic sclerosis. Rheumatology (Oxford) 2012;51:1347-56.
3. Elhai M, Guerini H, Bazeli R, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biological and radiographic findings. Arthritis Care Res (Hoboken) 2012;64:1244-9.
4. Ranque B, Authier FJ, Berezne A, et al. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007;1108:268-82. (Pubitemid 47528740)
5. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6. (Pubitemid 39573637)
6. Hasegawa M, Sato S, Fujimoto M, et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13. (Pubitemid 28088260)
7. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994;73:493-6.
8. Feghali CA, Bost KL, Boulware DW, et al. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
9. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
10. Gallucci RM, Lee EG, Tomasek JJ. IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 2006;126:561-8. (Pubitemid 43255642)
11. Saito F, Tasaka S, Inoue K, et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008;38:566-71. (Pubitemid 351758675)
12. Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;180:165-76.
13. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011;63:3575-85.
14. Sato S, Fujimoto M, Hasegawa M, et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004;43:1261-6. (Pubitemid 39359301)
15. O'Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 2012;51:1540-9.
16. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research Group Database. Ann Rheum Dis 2012;71:1355-60.
17. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group Database. Ann Rheum Dis 2007;66:754-63.
18. Lam GK, Hummers LK, Woods A, et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007;34:1636-7. (Pubitemid 47068007)
19. Allanore Y, Devos-François G, Caramella C, et al. Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis 2006;65:834-5. (Pubitemid 43799191)
20. Clements PJ, Wong WK, Hurwitz EL, et al. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999;42:2372-80. (Pubitemid 30333418)
21. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408-12.